ALW-II-41-27 is an Eph receptor tyrosine kinase inhibitor.
ALW-II-41-27 细胞实验
Cell Line
Concentration
Treated Time
Description
References
NCM460 colonic cells
50, 100, 200, 400 ng/mL
24 hours
ALW-II-41-27 significantly reversed LPS-induced oxidative stress and inflammation
Front Pharmacol. 2018 Mar 27;9:272.
KLE cells
1 µM and 10 µM
4 hours
Inhibition of EphA2 receptor significantly reduced Vd1 T cell-mediated killing of KLE cells
Front Immunol. 2021 Oct 7;12:752646.
Ishikawa cells
1 µM
4 hours
In EphA2-negative Ishikawa cells, ALW-II-41-27 did not significantly reduce cell killing
Front Immunol. 2021 Oct 7;12:752646.
Huh7 cells
0, 0.25, 0.5, 1, 2, 4 µM
48 hours
To evaluate the effect of ALW-II-41-27 on HCC cell proliferation, results showed that ALW significantly inhibited the growth of HCC cells.
Cell Rep. 2021 Feb 23;34(8):108765.
Hep3B cells
0, 0.25, 0.5, 1, 2, 4 µM
48 hours
To evaluate the effect of ALW-II-41-27 on HCC cell proliferation, results showed that ALW significantly inhibited the growth of HCC cells.
Cell Rep. 2021 Feb 23;34(8):108765.
SNU449 cells
0, 0.25, 0.5, 1, 2, 4 µM
48 hours
To evaluate the effect of ALW-II-41-27 on HCC cell proliferation, results showed that ALW significantly inhibited the growth of HCC cells.
Cell Rep. 2021 Feb 23;34(8):108765.
H2009 cells
1 µM
6 hours
To evaluate the effect of ALW-II-41-27 on NSCLC cell signaling pathways, results showed that ALW-II-41-27 inhibited phosphorylation of S6K1, S6, and BAD.
J Clin Invest. 2014 May;124(5):2037-49.
RAW macrophages
100 ug/mL
60 minutes
ALW-II-41-27 significantly inhibited Pc β-glucan-induced phosphorylation of both p38 and ERK1/2 and reduced TNF-alpha release
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0081123.
Mouse lung alveolar macrophages
100 ug/mL
60 minutes
ALW-II-41-27 significantly reduced TNF-alpha cytokine release from primary mouse lung alveolar macrophages induced by Pc β-glucans
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0081123.
H358 cells
1 µM
72 hours
To evaluate the effect of ALW-II-41-27 on NSCLC cell viability, results showed that ALW-II-41-27 significantly reduced cell viability.
J Clin Invest. 2014 May;124(5):2037-49.
ALW-II-41-27 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Yeast β-glucan-induced lung inflammation model
Intraperitoneal injection
0.1 mg/kg
20 hours before and 2 hours after
ALW-II-41-27 significantly reduced TNF-alpha protein levels in the lungs induced by yeast β-glucans
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0081123.
C57BL/6 mice
Trichinella spiralis-infected mouse model
Intraperitoneal injection
12.5, 25, 50, 100 mg/kg
Once daily for 7 consecutive days
ALW-II-41-27 significantly decreased gastrointestinal motility and visceral sensitivity in Trichinella spiralis-infected mice and inhibited oxidative stress and inflammation
Front Pharmacol. 2018 Mar 27;9:272.
NSG mice
HCC xenograft model
Intraperitoneal injection
15 mg/kg
Once daily for seven days
To evaluate the effect of ALW-II-41-27 on HCC tumor growth, results showed that ALW significantly inhibited tumor growth and even caused tumor regression.
Cell Rep. 2021 Feb 23;34(8):108765.
Mice
H358 xenograft model
Intraperitoneal injection
15 mg/kg
Twice daily for 14 days
To evaluate the effect of ALW-II-41-27 on NSCLC tumor growth, results showed that ALW-II-41-27 significantly inhibited tumor growth and induced tumor cell apoptosis.
搜索
